Funding round
Kallyope Series D
Kallyope, which works in neurological disease therapeutics discovery in New York, raised $236M in a Series D round announced on 15 Feb 2022, led by Mubadala and The Column Group, at a $1.30B post-money valuation. 15 firms took part. It is Kallyope's fourth venture round on record; the one before was a Series C in Mar 2020.
$236M
Amount raised
$1.30B
Post-money valuation
$1.06B pre-money
15
Investors
2 leads
18%
Stake sold
new money over the post-money
Valuation
What this round says about the price
This round priced Kallyope at $1.30B after the new money. The $236M bought investors about 18% of the company. It came 23 months after Kallyope's Series C. It is 52% of the $458M Kallyope has raised in the venture rounds on record. No later venture round is on record for Kallyope.
Investors
Who put money in
Mubadala and The Column Group led the round with 13 other firms.
Lead investors
- Mubadala backs 42 venture-backed companies new investor
- backs 24 venture-backed companies new investor
Also in the round
- Alexandria Venture Investments new investor
- Breakthrough Energy backs 113 venture-backed companies new investor
- backs 54 venture-backed companies new investor
- Euclidean Capital new investor
- backs 38 venture-backed companies new investor
- Lux Capital backs 194 venture-backed companies new investor
- backs 98 venture-backed companies new investor
- Two Sigma Ventures backs 60 venture-backed companies new investor
- StepStone Group new investor
- backs 21 venture-backed companies new investor
- Hartford Healthcare Endowment new investor
- Parkwood LLC new investor
- backs 17 venture-backed companies new investor
Use of proceeds
What the money is for
According to the announcement, the money goes to product development, scaling operations and working capital.
- Product development
- Scaling operations
- Working capital
Comparable rounds
How it compares
9 Series D rounds in Biotechnology within a year either side disclosed an amount; the median was $102M, and this round was 2.3 times the median. The closest in time, other companies' Series D rounds in Biotechnology:
| Company | Announced | Amount | Post-money | Led by |
|---|---|---|---|---|
| Biotechnology | 24 Feb 2022 | $110M | not disclosed | Cowen Healthcare Investments |
| Biotechnology | 9 Dec 2021 | $189M | not disclosed | HSG and CMB International Capital Corporation |
| Biotechnology | 1 Nov 2021 | $88M | not disclosed | not named |
| Biotechnology | 9 Sep 2021 | $195M | $1.00B | Redmile Group |
| Biotechnology | 21 Jul 2021 | $68M | not disclosed | Magnetar Capital |
| Biotechnology | 14 Jun 2021 | $75M | not disclosed | Mirae Asset Financial Group |
| Biotechnology | 3 Oct 2022 | $42M | not disclosed | 8VC and Mubadala Capital |
| Inari Biotechnology | 12 May 2021 | $208M | $1.20B | Flagship Pioneering and Alexandria Venture Investments |
Sources
Where this comes from
Reported by 5 sources.
Questions
Frequently asked
How much did Kallyope raise in its Series D round?
Kallyope raised $236M in its Series D round, announced in Feb 2022.
Who led Kallyope's Series D round?
Mubadala and The Column Group led it, with Alexandria Venture Investments, Breakthrough Energy, Casdin Capital, Euclidean Capital and Illumina Ventures and 8 more.
What was Kallyope's valuation at the Series D round?
$1.30B post-money ($1.06B pre-money).
How does it compare with other Series D rounds in Biotechnology?
9 Series D rounds in Biotechnology within a year either side disclosed an amount; the median was $102M, and this round was 2.3 times the median.